IRLAB Therapeutics AB
BioTech/Drugs - Göteborg, Göteborg, N/A
IRLAB Therapeutics AB Employees
IRLAB Therapeutics AB Senior Management
IRLAB Therapeutics AB Details
IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease and other CNS disorders. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market.
IRLAB Therapeutics AB Technologies
Email Providers
Outlook
Domain Name Services
Ports IT
CMS
WordPress.org
Other
Mobile Friendly
Analytics and Tracking
Google Analytics